Investment Rating - The investment rating for the company is "Buy" and is maintained [7]. Core Views - In 2024, the company achieved operating revenue of 5.37 billion yuan, a year-on-year decline of 11.6%, and a net profit attributable to shareholders of 170 million yuan, down 70.6% year-on-year. In Q4 2024, the operating revenue was 1.5 billion yuan, a decrease of 19.3% year-on-year, with a net profit of -190 million yuan [2][4]. - For Q1 2025, the company reported operating revenue of 1.08 billion yuan, a year-on-year decline of 20.8%, and a net profit of 100 million yuan, down 58.1% year-on-year [2][4]. - The company is focusing on overall resource efficiency and is undergoing a phase of adjustment in its skincare business, while the raw material business is growing steadily, and the high-margin medical terminal business is expanding rapidly [9]. Summary by Sections Financial Performance - In 2024, the raw material business generated revenue of 1.24 billion yuan, up 9.5% year-on-year, with international market expansion showing a growth of 17.7%, particularly in the Americas, Europe, and Southeast Asia, where growth exceeded 20% [9]. - The medical terminal business achieved revenue of 1.44 billion yuan, a year-on-year increase of 32%, with skin-related medical products growing by 43.6% [9]. - The functional skincare business reported revenue of 2.57 billion yuan, down 31.6% year-on-year, while the nutritional science business generated 80 million yuan, up 41% year-on-year [9]. Cost and Profitability - The company's gross margin improved by 0.8 percentage points year-on-year, with the raw material, medical terminal, and functional skincare gross margins changing by 0.9, 2.3, and -1.1 percentage points respectively [9]. - The net profit margin decreased by 6.5 percentage points year-on-year due to increased management expenses and changes in the organizational structure [9]. Future Outlook - The company is expected to see improvements in revenue and profit as it continues to adjust its skincare business and launch new products. The raw material business is expected to maintain a strong market position, and the medical beauty business is gradually contributing more to overall performance [9]. - EPS forecasts for 2025-2027 are 0.95, 1.33, and 1.67 yuan per share respectively [9].

[Table_Title] 研究报告 Research Report 26 May 2025 潮宏基 CHJ Industry (002345 CH) 店均高速增长，开店节奏稳健，注重品牌系统性工程建设 yy.kou@htisec.com ashley.fy.chen@htisec.com [Table_yemei1] 热点速评 Flash Analysis [Table_summary] (Please see APPENDIX 1 for English summary) 事件：5 月 23 日，海通国际海外消费组调研潮宏基总部，参加公司高管交流会。公司管理层表示终端增速自 2024 年 四季度开始提升，2025 年 4 月份店均增速约 45%，5 月初至 5 月 20 日增速约为 30%。5 月门店人流量在五一假期后 有所下滑，主要是受节日透支效应影响。 差异化打法应对市场竞争，产品设计突出年轻时尚风格。面对激烈市场竞争，管理层表示，其产品始终坚持差异化 定位，不做纯粹的"量+价"竞争，更重视客户体验和品牌美誉度。公司聚焦年轻消费群体，20-40 岁消费者占比约 80%，其中 25-35 岁区间为核心人 ...

公司报告 | 季报点评 信立泰（002294） 证券研究报告 创新产品持续落地，管线优势凸显成长潜力 事件 公司发布2024 年年报和2025 年第一季度报告，2024 年实现营业收入 40.12 亿元，同比增长 19.22%，归母净利润 6.02 亿元，同比增长 3.71%，盈利水 平稳健提升；2025 年第一季度的营业收入为 10.62 亿元，同比下降 2.64%， 归母净利润为 2 亿元，同比增长 0.03%。 加大销售推广力度，开拓市场 2024 年，销售费用率为 36.71%，同比增加 6.53pct，主要因为新上市产品 推广费用增加以及产品销售量增加；管理费用率为 6.78%，同比下降 1.74pct；研发费用率为 10.50%，同比下降 1.66pct。2025Q1，销售费用率 为 38.11%，同比增长 3.55pct；管理费用率为 6.62%，同比增长 0.05pct； 研发费用率为 10.18%，同比增加 0.32pct。 制剂驱动营收结构优化，创新产品板块比重提升 2025Q1 营业收入同比略有下降，造成收入同比下降的原因主要是受到仿制 药政策影响，相关产品收入占营收比重进一步降低。从产 ...

Investment Rating - The investment rating for the company is "Buy" and is maintained [7] Core Insights - In 2024, the company achieved operating revenue of 2.97 billion yuan, a year-on-year increase of 33.4%; net profit attributable to the parent company was 340 million yuan, up 31.7%; and net profit excluding non-recurring items was 330 million yuan, growing by 73.9%. In Q1 2025, the company reported operating revenue of 850 million yuan, a year-on-year growth of 28%; net profit attributable to the parent company was 140 million yuan, increasing by 22.1%; and net profit excluding non-recurring items was 130 million yuan, up 28.6% [2][4] Summary by Sections Business Performance - The company continues to solidify its big product strategy, with the main brand maintaining high growth. In 2024, revenue growth rates for each quarter were 39%, 19%, 26%, and 48%, with a significant acceleration in Q4. The main brand, Marubi, generated revenue of 2.06 billion yuan, a year-on-year increase of 31.7%. The two core products, the Little Red Pen Eye Cream and the Little Gold Needle, achieved GMV of 530 million yuan and 350 million yuan, respectively, with year-on-year growth of 146% and 96%. The Love Fire brand generated revenue of 910 million yuan, up 40.7%, with six foundation products each exceeding 100 million yuan in annual GMV [13] Financial Forecast - For 2025-2027, the company is expected to achieve net profits attributable to the parent company of 450 million yuan, 580 million yuan, and 750 million yuan, respectively, corresponding to EPS of 1.11 yuan, 1.44 yuan, and 1.87 yuan per share [13][17]

Investment Rating - The investment rating for the company is "Accumulate" [6] Core Views - The company reported a revenue of 2.02 billion yuan in 2024, representing a year-on-year growth of 4.3%, while the net profit attributable to shareholders was 660 million yuan, down 11.8% year-on-year. In Q1 2025, the revenue was 300 million yuan, a decline of 26.4% year-on-year, and the net profit attributable to shareholders was 90 million yuan, down 39.8% year-on-year [2][4] Summary by Sections Financial Performance - In 2024, the company achieved a total revenue of 2.02 billion yuan, with a net profit of 660 million yuan. The revenue growth was primarily driven by the cosmetics segment, which saw a 7.5% increase year-on-year, while the medical device segment remained stable with a 0.3% increase [9] - For Q1 2025, the company experienced a significant revenue drop of 26.4% year-on-year, attributed to proactive channel and product optimization efforts [9] Product and Channel Strategy - The company has successfully expanded its product offerings, with several products achieving annual sales exceeding 100 million yuan. The online sales channel has also seen substantial growth, with a 20% increase in revenue [9] - The company is focusing on enhancing its brand presence in e-commerce platforms, which has contributed to a significant increase in online sales [9] Profitability Metrics - The overall gross margin for 2024 was 82%, with a slight decrease of 0.5 percentage points. The net profit margin decreased by 6 percentage points to 32.8%, primarily due to an increase in sales expense ratio [9] - In Q1 2025, the net profit margin further declined by 6.7 percentage points, influenced by a rise in sales expenses and adjustments in product pricing [9] Future Outlook - The company is expected to stabilize its revenue and profitability through the formation of repeat purchases of core products and the gradual establishment of e-commerce strategies. EPS forecasts for 2025, 2026, and 2027 are projected to be 1.74 yuan, 1.89 yuan, and 2.05 yuan respectively [9]

丨证券研究报告丨 公司研究丨点评报告丨贝泰妮（300957.SZ） [Table_Title] 贝泰妮 2024 年报及 2025 一季报点评：产品渠 道阶段性调整，库存持续消化 报告要点 [Table_Summary] 公司公布 2024 年年报，全年实现营业收入 57.36 亿元，同比增长 3.87%，归母净利润 5 亿元， 同比下降 33.53%，2025Q1，公司实现营业收入 9.49 亿元，同比下降 13.51%；归母净利润 2834 万元，同比下降 83.97%。 分析师及联系人 [Table_Author] SAC：S0490514080004 SAC：S0490520080019 SFC：BUV258 李锦 罗祎 曾维朵 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 贝泰妮（300957.SZ） cjzqdt11111 [Table_Title 贝泰妮 20242]年报及 2025 一季报点评：产品渠 道阶段性调整，库存持续消化 [Table_Summary2] 事件描述 公司公布 2024 年年报，全年实现营业收入 57.36 亿元，同比增长 ...

Investment Rating - The report maintains a "Buy" rating for Weichai Power [6] Core Views - Weichai Power reported a revenue of 57.464 billion yuan for Q1 2025, representing a year-on-year growth of 1.92%. The net profit attributable to shareholders was 2.711 billion yuan, up 4.27% year-on-year. The projected net profits for 2025-2027 are 12.763 billion, 14.473 billion, and 15.396 billion yuan, corresponding to PE ratios of 10.39X, 9.16X, and 8.61X respectively. The report cites the old-for-new policy support, stabilization and recovery in the heavy truck industry, and stable cash flow as reasons for the positive outlook [2][4][10]. Summary by Sections Financial Performance - In Q1 2025, Weichai Power achieved a revenue of 57.464 billion yuan, with a year-on-year increase of 1.92%. The net profit attributable to shareholders was 2.711 billion yuan, reflecting a 4.27% year-on-year growth. The heavy truck sales for Q1 were 265,000 units, showing a year-on-year increase of 21.0% [2][4][10]. Strategic Initiatives - The company is advancing six strategic directions aimed at long-term development, focusing on adjusting product, business, and market structures. This includes accelerating the transition to new energy and digital intelligence, and expanding into large-diameter, aftermarket, non-road vehicles, and export businesses. The demand for high-end large-diameter power generation products is expected to increase, particularly in sectors like 5G data centers and mining [10]. Investment Outlook - The report projects net profits for 2025-2027 at 12.763 billion, 14.473 billion, and 15.396 billion yuan, with corresponding PE ratios of 10.39X, 9.16X, and 8.61X. The combination of supportive policies, industry recovery, and stable cash flow positions Weichai Power as a high-dividend quality stock, justifying the "Buy" rating [2][10].

Investment Rating - The investment rating for the company is "Buy" and is maintained [7] Core Views - The company reported a significant improvement in operational performance, with Q1 2025 revenue reaching 1.469 billion yuan, a year-on-year increase of 24.69%. The net profit attributable to shareholders was 93 million yuan, up 2.00% year-on-year, while the net profit excluding non-recurring items was 88 million yuan, reflecting a 2.48% increase year-on-year. However, the operating cash flow net amount decreased by 25.44% to 122 million yuan [2][4] - The company is positioned as a global leader in intelligent operating system products and technologies, leveraging its strategic advantages to drive the development of the smart industry amid a new wave of intelligentization. A new growth curve is expected to gradually open up [2][4] Summary by Sections Financial Performance - In Q1 2025, the company achieved a revenue of 1.469 billion yuan, representing a 24.69% increase year-on-year. The gross profit margin for Q1 was 36.28%, down 3.54 percentage points year-on-year, primarily due to increased personnel costs as the workforce grew from 13,119 in 2023 to 15,031. Operating costs increased by 32.02% year-on-year. However, the gross margin showed a significant recovery, increasing by 6.74 percentage points compared to the previous quarter [4][10] - The sales expense ratio, R&D expense ratio, and management expense ratio for Q1 were 3.54%, 19.20%, and 9.37%, respectively, showing a decrease compared to the same period last year [10] Growth Strategy - The company has outlined three main growth curves: 1. Capitalizing on the emerging trend of mobile operating systems to enter a rapidly growing market. 2. Enhancing existing business with edge AI to benefit from the increasing penetration of terminal intelligence. 3. Combining edge AI with innovative businesses, such as mobile robotics platforms, to fully leverage the opportunities presented by edge intelligence [10] - Recent product launches, including Drip OS 1.0 Evo, TurboX AI glasses, and mobile robot AMR, highlight the company's breakthroughs in AI-native operating systems and edge intelligence [10] Market Positioning - The company is firmly committed to its "operating system + edge intelligence" strategy, with a strong positioning expected to open up a new growth curve. The company has established long-term collaborations with leading players in the industry, including chip manufacturers and cloud service providers, to expand its ecosystem [10] - The company is well-positioned in the smart industry, aligning its business layout with the trend of value growth shifting from cloud to edge, and is expected to benefit from every wave of terminal intelligence opportunities [10]

店均高速增长，开店节奏稳健，注重品牌系统性工程建设 Strong Average Store Growth, Steady Expansion Pace, Focusing on Systematic Brand Development 寇媛媛 Yuanyuan Kou 陈芳园 Ashley Chen [Table_Title] 研究报告 Research Report 26 May 2025 潮宏基 CHJ Industry (002345 CH) yy.kou@htisec.com ashley.fy.chen@htisec.com [Table_yemei1] 热点速评 Flash Analysis [Table_summary] (Please see APPENDIX 1 for English summary) 事件：5 月 23 日，海通国际海外消费组调研潮宏基总部，参加公司高管交流会。公司管理层表示终端增速自 2024 年 四季度开始提升，2025 年 4 月份店均增速约 45%，5 月初至 5 月 20 日增速约为 30%。5 月门店人流量在五一假期后 有所下滑，主要是受节日透支效应影响。 ...

Investment Rating - The investment rating for the company is "Outperform the Market" [5][7]. Core Views - The company's performance in 2024 was impacted by a global agricultural chemical destocking cycle, but a significant improvement is expected in Q1 2025 due to price increases in several main products [2][30]. - The company reported a revenue of 4.237 billion yuan in 2024, a slight increase of 0.32% year-on-year, while the net profit attributable to shareholders was 81 million yuan, up 31.11% year-on-year [2][6]. - The company is experiencing a recovery in product prices, particularly in key products like Mancozeb and Avermectin, which have seen substantial price increases since March 2024 [3][34]. Summary by Sections Financial Performance - In Q1 2025, the company achieved a revenue of 1.211 billion yuan, a year-on-year increase of 22.28%, and a net profit of 108 million yuan, marking a turnaround from a loss in the previous year [30]. - The company’s revenue and net profit forecasts for 2025-2027 are 4.958 billion yuan, 5.255 billion yuan, and 5.513 billion yuan, with net profits of 402 million yuan, 478 million yuan, and 522 million yuan respectively [5][50]. Product Pricing and Market Trends - Key products such as Mancozeb and Avermectin have seen price increases, with Mancozeb's price rising from 23,500 yuan/ton to 25,000 yuan/ton since March 2025 [3][33]. - The price of the company's other products, including Bacillus thuringiensis and the veterinary drug Tylosin, has also increased significantly, indicating a positive trend in product demand [34][37]. New Business Developments - The company has accelerated its new business layout, including the acquisition of a 51% stake in DeYan ZhiChuang, which focuses on AI-driven pesticide development [4][38]. - Strategic partnerships with companies like BASF are expected to enhance the development and commercialization of new pesticides in China [4][38]. Market Position and Competitive Landscape - The company holds a strong market position in the agricultural chemicals sector, with a significant share in the fungicide market and ongoing expansion into international markets, particularly in Brazil [3][33]. - The company is actively working on new product development and technological advancements to maintain its competitive edge in the industry [4][39].